Why Pharmaceutical Companies Outsource Clinical Trials to CROs

Running a Phase III clinical trial in-house is possible. However, it requires significant infrastructure, global site networks, regulatory expertise, data systems, and experienced teams. Even large pharmaceutical companies do not run all trials internally.

For midsize pharma, biotech, and emerging companies, building this infrastructure for every program is neither practical nor cost-effective. This is exactly why outsourcing clinical trials to CROs has become the standard operating model across the pharmaceutical industry.

The capabilities required to run modern, multinational clinical trials are too specialized and globally distributed. As a result, companies increasingly rely on CRO partnerships to execute trials efficiently.

The global CRO services market reflects this shift. The market reached approximately USD 77 billion in 2024 and is projected to grow to USD 162.1 billion by 2033, representing a compound annual growth rate of 8.6%[4]. This sustained growth confirms that outsourcing clinical trials to CROs is not a temporary trend but a long-term structural feature of the industry.

What Is a Clinical Research Organization (CRO)?

A Clinical Research Organization (CRO) provides clinical research services to pharmaceutical companies, biotech firms, and medical device organizations on a contracted engagement basis.

At the core, CROs manage clinical trial operations such as site selection, patient recruitment, monitoring, and study closeout through advanced clinical trial services.

However, their capabilities now extend far beyond operations.

A full-service CRO typically provides:

• Regulatory affairs and submission support via regulatory submission services
• Clinical data management and eClinical systems supported by clinical trial data management
• Biostatistics and statistical programming through biostatistics services
• Medical documentation and reporting through medical writing services
• Pharmacovigilance and safety reporting
• Quality assurance and GCP compliance
• Patient recruitment strategies
• Decentralized trial capabilities

Under ICH E6(R3) Good Clinical Practice, the updated guideline adopted by ICH in January 2025, sponsors remain ultimately responsible for trial quality and data integrity, even when activities are delegated to CROs and other service providers[1].

Why Pharmaceutical Companies Are Outsourcing Clinical Trials to CROs

1. Cost Efficiency Without Sacrificing Capability

Drug development economics have changed materially over the past two decades. The Tufts Center for the Study of Drug Development estimates the average cost to develop and win marketing approval for a new prescription drug at approximately USD 2.6 billion, with Phase III trials representing the most resource-intensive cost component[7]. For a single Phase III program, this can translate into hundreds of millions of dollars in trial-specific spend before any commercial return.

The structural problem with building this capability internally is not the absolute cost (large pharma can absorb it) but the asset utilization profile. Phase III infrastructure (validated EDC platforms, global monitoring teams, regulatory affairs staff in multiple jurisdictions, qualified site networks) is required intensively for two to four years per program and then sits underutilized between programs. For mid-size pharma and biotech with concentrated pipelines, the math is harder still: amortizing fixed infrastructure across one or two active programs makes the per-trial overhead untenable.

Outsourcing converts these fixed costs into variable, program-linked costs. CROs amortize their infrastructure across many sponsors simultaneously, which is a structural advantage that no individual sponsor can replicate at scale. The downstream consequence for sponsors is a fundamental shift in capital allocation: spending that would otherwise be locked in operational overhead becomes available for the science, the molecule pipeline, and commercial preparation, areas where sponsor differentiation actually matters.

2. Faster Time-to-Market Through Established Infrastructure

Speed in clinical research is not a soft preference; it has direct financial consequences. Each day of delay in late-stage drug development carries a measurable opportunity cost in lost revenue exclusivity, particularly for blockbuster-class assets[7]. Beyond the direct revenue impact, every additional month a program runs increases burn rate, extends investor timelines, and exposes the program to competitive entrants in the same therapeutic space.

The startup phase, from protocol finalization through the first patient enrolled, is where most preventable delay occurs. A sponsor building infrastructure from scratch faces a sequential dependency chain: site identification, regulatory submissions in each target country, ethics committee submissions, vendor selection (eClinical, central lab, IRT), monitor recruitment and training, and contract negotiations with each site. This process is rarely under 12 months for a multi-country program and is frequently 18 to 24 months for first-time global sponsors.

CROs collapse this timeline because the dependency chain is largely pre-resolved: site relationships exist, regulatory teams have submission templates ready, eClinical platforms are validated and operational, and monitoring teams are deployed. The practical implication is that a program engaging a fit-for-purpose CRO can typically begin enrollment substantially earlier than a sponsor building internally, a difference that translates directly into earlier market entry and earlier revenue recognition. Regulatory pathways like the FDA’s Accelerated Approval program, which compress review timelines for serious conditions with unmet medical need, amplify this effect: speed to enrollment becomes speed to filing, and speed to filing determines competitive positioning[8].

3. Access to Global Patient Populations

Modern protocols increasingly require multi-country enrollment for two distinct reasons: enrollment feasibility (rare diseases, biomarker-stratified subgroups, and indications with intense competition for the same patient pool) and regulatory acceptability (FDA, EMA, CDSCO, PMDA, and other agencies expect data from populations representative of intended markets). For most programs beyond Phase II, a single-country trial is operationally and regulatorily insufficient.

The challenge of building global enrollment capability internally is not the regulatory paperwork; it is the depth of relationships required at every level. Each country has its own regulatory pathway (CTA in the EU, CTN in Australia, NMPA review in China, CDSCO approval in India, IND/NDA review with the US FDA), its own ethics committee structure, its own site contracting norms, its own data privacy regime (GDPR, HIPAA, China PIPL, India DPDPA), and its own investigator community whose engagement with any given sponsor depends heavily on prior history. Building these relationships from zero in 10 to 15 countries simultaneously is a multi-year undertaking with high failure risk for first-time global sponsors.

CROs operate in this space continuously. Their regulatory teams maintain active submission histories in dozens of jurisdictions, including FDA, EMA, and CDSCO (India). Their site networks include investigators who have already enrolled patients in similar indications. Their data infrastructure is configured for cross-border data flow under current privacy frameworks. The consequence for sponsors is access to operational depth that cannot be reasonably built program-by-program. Just as importantly, sponsors gain access to enrollment timelines that have been validated against actual prior performance rather than projected from theoretical site capacity.

4. Regulatory Expertise at Submission Level

Regulatory submissions are where the cumulative quality of trial conduct gets tested. An IND, NDA, BLA, MAA, or CDSCO CT/NDA submission is not just a document package; it is the artifact through which months or years of trial execution are evaluated by an agency that has seen thousands of similar submissions and knows exactly which deficiencies precede inspection findings. Submission quality is therefore a leading indicator of approval timeline and approval probability.

The expertise required spans three distinct competencies. First, regulatory writing, which is the ability to construct submissions that anticipate reviewer questions and address them in the primary document rather than in subsequent correspondence cycles. Second, regulatory strategy, which is the judgment to determine which endpoints, comparators, and trial designs will be acceptable to the target agency, often involving pre-submission meetings that shape the program years before filing. Third, inspection readiness, which is the operational discipline to ensure that the trial conduct represented in the submission can withstand a regulatory inspection of source data, monitoring records, and quality systems.

CROs that have completed multiple successful submissions to FDA, EMA, and CDSCO (India) bring institutional memory of agency expectations that is genuinely difficult to acquire from outside. They know which questions have been raised in similar programs, which design choices have been challenged, and which documentation gaps have triggered Complete Response Letters, Day 120 List of Questions, or CDSCO clarification queries. The practical consequence for sponsors, particularly those approaching their first major submission, is that this institutional memory shortens the regulatory cycle and reduces the probability of approval-delaying deficiencies. Under ICH E6(R3), which places stronger emphasis on sponsor accountability for quality even in outsourced programs, the regulatory dimension of CRO selection has become more important, not less[1].

5. Technology Access Without Capital Investment

Modern clinical trials depend on a stack of validated technology that did not exist in production form 15 years ago: Electronic Data Capture (EDC) systems, Clinical Trial Management Systems (CTMS), electronic Trial Master Files (eTMF), Interactive Response Technology (IRT), risk-based monitoring platforms, electronic Patient-Reported Outcomes (ePRO), and increasingly, AI-enabled protocol design and predictive site selection tools. Each of these systems requires not just licensing but also implementation, validation against 21 CFR Part 11 and EU Annex 11 requirements, integration with adjacent systems, and ongoing administration.

For a sponsor running a single program, the build-versus-buy decision rarely favors building. A Veeva Vault, Medidata Rave, or Oracle InForm deployment requires 6 to 12 months of implementation and ongoing administration costs that scale with program complexity. Validation alone is a substantial undertaking, and validation has to be re-executed every time the system is updated. The opportunity cost is significant: implementation time is time not spent on the science, and validation expertise is not a sponsor differentiator.

CROs operate these platforms continuously across their entire client portfolio, which means the validation burden, the integration cost, and the operational expertise are all already absorbed. Sponsors gain access to mature, inspection-ready technology infrastructure on a program-linked basis without the capital expenditure or the operational risk of standing it up internally. The strategic implication is that technology choices stop being a barrier to program initiation. Sponsors can focus on whether the right system is being used for the right reason, not on whether they can implement it in time.

A Real-World Scenario

Consider a mid-sized pharmaceutical company developing a treatment for a rare metabolic disease, with a global patient population of fewer than 5,000 confirmed cases. Running this program internally would require recruiting clinical operations staff with rare disease experience, establishing investigator relationships at the 30 to 50 specialist centers worldwide that treat the condition, navigating regulatory submissions across the United States, the European Union, India, and at least two additional Asian markets, and implementing the eClinical infrastructure to support a small but geographically dispersed enrollment. Realistically, this preparation phase consumes 18 to 24 months before the first patient is enrolled, and during those months the cash burn of a full clinical operations team is being absorbed against zero scientific progress.

Engaging an experienced rare disease CRO compresses this dramatically. Feasibility assessment can begin within weeks rather than months because the CRO already knows which sites have enrolled comparable indications and which investigators have active patient panels. Regulatory submissions move on parallel tracks because the CRO’s regional offices have active submission queues with FDA, EMA, and CDSCO. eClinical platforms are operational on day one. Patient recruitment leverages existing relationships rather than cold outreach. The end result is not just a faster timeline but a more predictable one, supported by enrollment forecasts that are grounded in the CRO’s prior performance data rather than theoretical projections.

Key Benefits of Outsourcing Clinical Trials to CROs

Synthesizing the discussion above, CRO partnerships deliver value through several reinforcing mechanisms: a variable cost structure that converts fixed infrastructure spending into program-linked operational expense; faster trial startup and execution through pre-existing site networks, regulatory relationships, and validated technology; access to deep therapeutic and regional expertise that would take years to build internally; advanced eClinical and monitoring technology without capital investment; improved regulatory compliance and inspection readiness through institutional submission experience with FDA, EMA, and CDSCO; and operational scalability that allows sponsors to scale resources up or down based on program phase. Beyond these direct benefits, CROs provide specialized expertise across therapeutic areas and trial phases that allows sponsors to focus internal capacity on the science and strategic decisions that only they can own.

Challenges of Outsourcing: What Decision-Makers Need to Know

Outsourcing works. It also comes with real tradeoffs that sponsors who have gone through it, not just planned it, consistently identify.

Sponsor Oversight Remains Non-Negotiable

ICH E6(R3), the Good Clinical Practice guideline adopted by ICH in January 2025 and effective in major regulatory regions from July 2025, is unambiguous on this point: the sponsor retains ultimate accountability for trial quality and data integrity, regardless of what is delegated to a CRO or any other service provider[1]. The guideline explicitly requires sponsors to ensure oversight of any trial-related duties and functions carried out on their behalf, including activities subcontracted by the contracted CRO to other parties[1]. Organizations that outsource and then disengage from operational oversight create the conditions for quality failures that surface at the worst possible time, during a regulatory inspection or an advisory committee review.

This is reinforced by inspection history. Cross-industry analyses of FDA, EMA, MHRA, and CDSCO inspection outcomes have consistently identified sponsor oversight and vendor management among the most frequent categories of inspection findings[3]. Effective outsourcing therefore requires active sponsor oversight: dedicated internal personnel who understand what the CRO is doing, structured governance touchpoints, clear escalation protocols, and audit rights exercised regularly. ICH E6(R3) further requires sponsors to maintain risk-based oversight throughout the trial lifecycle and document oversight decisions and actions, meaning fully-outsourced sponsors face heightened inspection risk if their oversight is not demonstrably documented[1].

Communication and Accountability Gaps

Independent industry research published by Applied Clinical Trials in 2026, based on interviews conducted in mid-2025 with 25 biopharmaceutical executives and outsourcing leaders (CEOs, CSOs, vice presidents of clinical operations, directors, and study managers), identified a consistent pattern: sponsors feel CRO teams understand protocols well but struggle with proactive problem-solving[2]. There is a perception that CRO teams expect direction rather than demonstrating initiative when challenges arise, whether those are enrollment shortfalls, site performance issues, or protocol deviations.

This is a governance problem as much as a CRO quality problem. Contracts that do not specify escalation standards, performance metrics, and CRO accountability for operational recommendations will get operational execution without strategic partnership. The same research notes a distinct shift away from traditional full-service CRO arrangements toward hybrid resourcing strategies that combine in-house expertise, trusted consultants, and selective outsourcing, partly as a sponsor response to communication and accountability concerns[2].

Change Orders and Cost Predictability

The same 2026 industry research found that sponsors using preferred-provider CRO models reported spending a higher percentage of their time discussing out-of-scope activities and negotiating change orders compared to sponsors using competitive bid models, eroding much of the cost predictability that preferred-provider relationships are supposed to deliver[2]. Protocol amendments, scope changes, and site additions all typically generate change orders, and for smaller biotech sponsors with limited financial flexibility, the unpredictability of change orders introduces material risk to development program forecasting[2].

Building realistic contingency into project budgets and negotiating change order governance upfront (clear definitions of what triggers a change order, escalation paths, and approval thresholds) protects against mid-study financial surprises. Contractual clarity at the outset is operationally cheaper than renegotiating mid-trial.

Therapeutic Area Fit Versus General Capability

A CRO that has successfully run oncology trials is not automatically the right partner for a rare metabolic disease program, even if their capabilities list includes both. Experienced sponsors seek CROs whose therapeutic depth matches the specific indication, not just the therapeutic area category. Prior enrollment performance in comparable patient populations, established investigator relationships in the right disease community, and biostatistical experience with appropriate endpoint design matter substantially more than general capability statements.

This consideration becomes particularly material in indications with small patient pools. In a rare disease trial enrolling 100 patients globally, the CRO’s existing relationships with the 30 to 50 investigators worldwide who routinely treat that condition will shape enrollment timelines more decisively than any operational efficiency gains from a larger but less specialized partner. The downstream consequence of misalignment here (slower enrollment, higher per-patient cost, weaker data quality) is rarely recoverable mid-program.

How to Choose the Right CRO: A Practical Checklist

Selecting a CRO is a decision that will be lived with for three to five years. The following questions are the ones that experienced sponsors, not first-timers, ask during evaluation:

Category	Questions to Ask
Therapeutic Expertise	Has the CRO run trials in your exact indication, not just your therapeutic area? Can they name the investigators they have worked with and show enrollment performance data from comparable programs?
Regulatory Track Record	What is their submission acceptance rate with FDA, EMA, and CDSCO (India)? Do they have in-house regulatory staff, or do they rely on third-party consultants for filings in your target jurisdictions?
Technology & Data	What eClinical systems do they operate? Are they proprietary or best-of-breed platforms? How do they handle data migration and continuity if the partnership ends?
Operational Footprint	Which countries do they have established site relationships in? Can they demonstrate actual enrollment timelines versus projected timelines from past trials?
Oversight Model	What is their standard monitoring plan, and how is it adapted for risk under ICH E6(R3)? Who is the senior contact accountable for your program, and what is their experience level?
Financial Structure	What triggers change orders, and what is their historical frequency per trial? Do they offer performance-based contracting or milestone-linked payment structures?

One principle cuts across all of these: evaluate the team you will actually work with, not the team that presented the proposal. The seniority and experience level of the day-to-day study team, not the business development executives, determines what you actually get.

The Future of CRO Partnerships

The CRO industry is in the middle of a structural shift from transactional vendor relationships toward strategic co-development partnerships. Major CROs that reported strong 2025 performance are not growing primarily by winning more competitive bids; they are growing by deepening relationships with sponsors who have moved to preferred provider or functional service provider (FSP) models.

FSP models, in which a sponsor outsources specific functions (for example, monitoring, data management, medical writing) rather than entire programs, have become the primary outsourcing approach for the world’s top 10 biopharma companies and are increasing in adoption among the next 10 largest organizations[6]. Industry tracking estimates the global FSP market at approximately USD 17.9 billion in 2024, projected to reach USD 38.56 billion by 2033 at a CAGR of 8.9%[5]. A 2025 industry survey of 150 biopharmaceutical leaders found that approximately nine in ten now use FSP or hybrid FSP frameworks for clinical development[6], reflecting how mainstream the model has become. FSP arrangements give sponsors more control over program governance while still accessing CRO capabilities in functions where internal capacity is limited.

AI integration is accelerating differentiation within the CRO market. By 2026, AI-enabled protocol design, predictive site selection, digital endpoints, and hybrid patient-centric models have become foundational capabilities for leading CROs. Those that cannot demonstrate these capabilities are increasingly losing preferred-provider status with sophisticated sponsors who have built their own evaluation frameworks around technology maturity.

The trajectory is toward closer, longer-horizon partnerships where CROs function not as vendors executing defined tasks, but as co-architects of development strategy. For sponsors, this requires more careful partner selection upfront and more deliberate governance throughout, but the payoff in execution quality, timeline predictability, and regulatory outcome is measurable.

Conclusion: Making Outsourcing Work

Outsourcing clinical trials to CROs is not a decision that requires justification in 2026. It is the default operating model for the vast majority of drug development programs. The question is not whether to outsource, but how to structure the partnership for the specific program and the specific organization.

The sponsors who get the most from CRO partnerships treat them as operational relationships with clear governance, not transactional arrangements where the handoff ends accountability. They select partners based on therapeutic fit and demonstrated performance, not capability lists. They maintain active oversight throughout the program, not just at key milestones.

The CRO industry has earned its position in the drug development value chain because it solves a genuine structural problem. Used well, a quality CRO partnership accelerates programs, improves regulatory outcomes, and allows sponsor organizations to stay focused on the science and strategy that only they can own.

Biosphere CRO has been providing clinical research services since 2012, with capabilities spanning clinical operations, remote monitoring through the e-Prudent platform, data management, statistical analysis, regulatory affairs (including FDA, EMA, and CDSCO submissions), medical writing, and pharmacovigilance. If you are evaluating outsourcing options for your next program, we are ready to have that conversation.

Frequently Asked Questions

Why do pharmaceutical companies use CROs?

Pharmaceutical companies use CROs to access specialized operational capabilities (site networks, regulatory expertise, therapeutic area depth, technology platforms, trained monitoring staff) without building and maintaining that infrastructure permanently in-house. For programs that run for three to five years and then end, building internal infrastructure for each program is neither economically rational nor operationally practical. CROs allow sponsors to convert fixed infrastructure costs into variable program costs, access global patient populations through established site relationships, and maintain focus on scientific and strategic priorities.

What are the main benefits of outsourcing clinical trials?

The core benefits are cost efficiency through variable rather than fixed infrastructure costs, faster startup timelines through pre-established site networks and regulatory relationships, access to global patient populations across multiple geographies, depth of therapeutic expertise and regulatory knowledge that would take years to build internally, and access to validated eClinical technology platforms without capital expenditure. Operational flexibility, the ability to scale a trial team up or down based on program phase, is an additional benefit that sponsors with variable pipeline activity particularly value.

Are CROs cost-effective for small and midsize pharma companies?

Yes, and often more significantly so than for large pharma. Large pharmaceutical companies outsource selectively, maintaining in-house capabilities for their highest-priority programs. Smaller companies with limited infrastructure gain disproportionate benefit from CRO partnerships because they are effectively accessing large-scale operational capabilities without the overhead of building them. For a biotech with a single pipeline asset, a CRO partnership may be the only viable path to a Phase III trial within a realistic timeline and budget.

What are the risks of outsourcing clinical trials?

The main risks are reduced direct control over day-to-day execution, potential communication gaps between sponsor and CRO teams, change order costs that erode budget predictability, and therapeutic area mismatch when CRO general capabilities do not match the specific demands of the indication. These risks are manageable with deliberate governance: clear accountability structures, defined escalation protocols, performance-based contracting, and active sponsor oversight throughout the program rather than only at milestone reviews.

How do I select the right CRO for my clinical trial?

Selection should be grounded in demonstrated therapeutic area performance rather than general capability claims. Key evaluation criteria include prior enrollment performance in comparable indications, investigator network depth in the target patient population, regulatory submission track record with the target agency (FDA, EMA, CDSCO, or other), technology platform maturity and GCP validation status, and the experience level of the actual study team (not the proposal team). Reference checks with past sponsors in similar programs are typically more informative than any RFP response.

What is the difference between full-service outsourcing and FSP models?

Full-service outsourcing involves engaging a CRO to manage most or all aspects of a clinical trial program under their operational control. A Functional Service Provider (FSP) model involves outsourcing specific functions such as clinical monitoring, data management, medical writing, or biostatistics, while the sponsor retains program management and governance. FSP models are growing among large pharma organizations that want CRO capabilities in specific areas without giving up overall program control. The right model depends on the sponsor’s internal capacity, the program’s complexity, and the organization’s preference for operational oversight.

References

[1] International Council for Harmonisation. ICH Harmonised Guideline: Good Clinical Practice E6(R3), Step 4 Final Version. Adopted 6 January 2025. Available at: https://database.ich.org/sites/default/files/ICH_E6(R3)_Step4_FinalGuideline_2025_0106.pdf

[2] Applied Clinical Trials. Resourcing and Outsourcing Trends in Drug Development. Published 25 March 2026. Based on interviews conducted in June and July 2025 with 25 biopharmaceutical leaders including CEOs, CSOs, vice presidents of clinical operations, directors, and study managers. Available at: https://www.appliedclinicaltrialsonline.com/view/resourcing-outsourcing-trends-drug-development

[3] U.S. Food and Drug Administration. E6(R3) Good Clinical Practice (GCP), Final Guidance for Industry. Issued September 2025. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r3-good-clinical-practice-gcp

[4] IMARC Group. CRO Services Market Report 2025 to 2033. Global market valued at USD 77.0 billion in 2024 and projected to reach USD 162.1 billion by 2033 at a CAGR of 8.6%. Available at: https://www.imarcgroup.com/contract-research-organization-services-market

[5] Astute Analytica (via GlobeNewswire). Functional Service Provider (FSP) Market to Reach US$ 38.56 Billion by 2033. Published 8 September 2025. Global FSP market valued at USD 17.9 billion in 2024, projected to reach USD 38.56 billion by 2033, CAGR 8.9%. Available at: https://www.globenewswire.com/news-release/2025/09/08/3146294/0/en/Functional-Service-Provider-FSP-Market-to-Reach-US-38-56-Billion-by-2033-Astute-Analytica.html

[6] PPD (Thermo Fisher Scientific). 2025 FSP Trends Report: The Pulse Survey of 150 Biopharmaceutical Leaders. Survey identified that approximately 9 in 10 biopharmaceutical organizations now use FSP or hybrid FSP frameworks for clinical development. Available at: https://www.ppd.com/blog/fsp-outsourcing-challenges-trends-opportunities-2025/

[7] DiMasi JA, Grabowski HG, Hansen RA. Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics 2016;47:20 to 33. Tufts Center for the Study of Drug Development estimate of average drug development cost at approximately USD 2.6 billion per approved compound. Cost-of-delay updates in: Smith Z, DiMasi J, Getz K. Tufts CSDD Impact Report, July/August 2024;26(4). Tufts CSDD reference: https://csdd.tufts.edu/cost-study

[8] U.S. Food and Drug Administration. Accelerated Approval Program. Available at: https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program